Loading...

ABCL ABCELLERA BIOLOGICS INC Business Restructuring 8-K Filing

BCLL

BCL

ABCELLERA BIOLOGICS INC

(ABCL)

2023 8-K

Show Summary

Summary

Financial Statements

Clinical Trials

Clinical Trials

Regulatory Compliance

Financial Statements

Earnings Results

Management Change

Earnings Announcement

Earnings Reports

Annual Meeting of Shareholders

Departure of Directors

Financial Results Announcement

Workforce Reduction

Ownership of Antibody Drug ...

Annual Meeting of Shareholders

Investment Agreement

Regulation FD Disclosure

External Links:

AbCellera Biologics Inc. announced a workforce reduction of approximately 10% to focus on clinical development of new antibody medicines, incurring an estimated cash expense of $2.5 million.

AI Assistant

ABCELLERA BIOLOGICS INC

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.